Economic evaluation of carfilzomib (car), ixazomib (ixa), elotuzumab (elo), or daratumumab (dar) with lenalidomide & dexamethasone (len+dex) vs len+dex in relapsed/refractory multiple myeloma (r/r mm)

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: ABRAHAM, Ivo (University Of Arizona, Pharmacy Practice and Science, Tucson, United States)
  • Co-author(s): Nimer Alsaid: Center for Health Outcomes and PharmacoEconomic Research, University Of Arizona College of Pharmacy, Tucson, United States
    Ali McBride: Banner University Medical Center , Tucson, United States;, University of Arizona Cancer Center, Tucson, United States
    Abdulaali Mutairi: Center for Health Outcomes and PharmacoEconomic Research, University Of Arizona College of Pharmacy, Tucson, United States
    Amit Agarwal: Banner University Medical Center, Tucson, United States;, University of Arizona Cancer Center, Tucson, United States
    Faiz Anwer: Banner University Medical Center, Tucson, United States;, University of Arizona Cancer Center, Tucson, United States
    Ivo Abraham: Center for Health Outcomes and PharmacoEconomic Research, University Of Arizona College of Pharmacy, Tucson, United States
  • Abstract:

    Methods

    Network meta-analysis [NMA] and Bücher method of indirect comparison were used to indirectly estimate comparative progression-free survival (PFS) efficacy. A 2-state Markov model (progression-free, progressed/death) was specified. Inputs included: cost of chemotherapy, administration, adverse events (AE) management, disease monitoring;..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login